ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

doi:10.1182/blood-2011-08-368225

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

Blood - 22 Dec 2011

Metzeler Klaus H, Becker Heiko, Maharry Kati, Radmacher Michael D, Kohlschmidt Jessica, Mrózek Krzysztof, Nicolet Deedra, Whitman Susan P, Wu Yue-Zhong, Schwind Sebastian, Powell Bayard L, Carter Thomas H, Wetzler Meir, Moore Joseph O, Kolitz Jonathan E, Baer Maria R, Carroll Andrew J, Larson Richard A, Caligiuri Michael A, Marcucci Guido, Bloomfield Clara D

Abstract excerpt

The associations of mutations in the enhancer of trithorax and polycomb family gene ASXL1 with pretreatment patient characteristics, outcomes, and gene-/microRNA-expression profiles in primary cytogenetically normal acute myeloid leukemia (CN-AML) are unknown. We analyzed 423 adult patients for ASXL1 mutations, other prognostic gene mutations, and gene-/microRNA-expression profiles. ASXL1 mutations were 5 times...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to CCAAT-Enhancer-Binding Proteins

Share to Kaplan-Meier Estimate

Share to Leukemia, Myeloid

Share to MicroRNAs

Share to Multivariate Analysis

Share to Nucleophosmin

Source

Open in PubMed Open full text

Identifiers

PMID: 22031865
DOI: 10.1182/blood-2011-08-368225
PMCID: PMC3245212

Genes

ASXL1
ELN
EFS
FLT3
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.PMID 22031865Read ↗

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.Semantic proximity Read ↗

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study GroupSemantic proximity Read ↗

The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing.Semantic proximity Read ↗

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.Semantic proximity Read ↗

ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia.Semantic proximity Read ↗

Expression and prognostic impact of lncRNAs in acute myeloid leukemia.Semantic proximity Read ↗

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySemantic proximity Read ↗

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.Semantic proximity Read ↗

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemiaSemantic proximity Read ↗

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.Semantic proximity Read ↗

ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification.Semantic proximity Read ↗

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.